Clinical Scorecard: In-depth Examination of Fatty Acid Desaturase 3's Role in Clear Cell Renal Cell Carcinoma: Implications for Tumor Development, Immune Environment, and Patient Prognosis
At a Glance
Category
Detail
Condition
Clear Cell Renal Cell Carcinoma (ccRCC)
Key Mechanisms
Involvement of Fatty Acid Desaturase 3 (FADS3) in lipid metabolism and tumor progression.
Target Population
Patients diagnosed with clear cell renal cell carcinoma.
Care Setting
Oncology and urology clinics.
Key Highlights
FADS3 is upregulated in ccRCC and associated with poor prognosis.
FADS3 expression remodels the tumor immune microenvironment (TIME).
Knockdown of FADS3 significantly inhibits ccRCC cell proliferation, migration, and invasion.
FADS3 may activate the PI3K/Akt signaling pathway to promote tumor progression.
Targeting lipid metabolism could enhance immunotherapy effectiveness in ccRCC.
Guideline-Based Recommendations
Diagnosis
Utilize transcriptomic datasets for differential analysis of ccRCC.
Management
Consider immunotherapy with ICIs as first-line treatment for advanced ccRCC.
Monitoring & Follow-up
Monitor FADS3 expression levels as a potential prognostic marker.
Risks
Assess for intrinsic or acquired resistance to immunotherapy.
Patient & Prescribing Data
Individuals with advanced clear cell renal cell carcinoma.
Combination therapies targeting lipid metabolism may improve treatment outcomes.
Clinical Best Practices
Incorporate lipid metabolism assessment in ccRCC treatment planning.
Evaluate the immune microenvironment in ccRCC patients to tailor therapies.
